Published in Cancer Weekly, March 30th, 1998
GenQuest receives an up-front payment, and if the option is exercised by Introgen, also receives undisclosed research funding, milestone payments and royalties on potential product sales.
GenQuest holds exclusive worldwide rights to the mda-7 gene. Preclinical data suggest that mda-7 is a universal tumor suppressor gene. Expression of this gene in a variety of different tumor cells results in loss of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.